The SARS-CoV-2 crisis, and the prophylactic mRNA vaccines developed in response to it, brought mRNA to the forefront as an exciting new frontier in medicine. Developers looking to unlock the potential of mRNA therapeutics, however, must overcome a significant challenge—selecting and sourcing raw materials that will allow them to create a consistent therapeutic product at scale.
In this guidebook, developed in collaboration with BioPharma Dive, we share insights into: